A latest research by Prof. Tadej Battelino and team which got published in ‘Diabetes Technology and Therapeutics’ compared the efficacy of the use of faster-acting and standard insulin aspart with hybrid automated insulin delivery (AID) in active youth with type 1 diabetes.

      In this double-blind, multinational, randomized, crossover trial, 30 children and adolescents with type 1 diabetes (16 females; aged 15.0±1.7 years; baseline HbA1c 7.5±0.9%) underwent two unrestricted four-week periods using hybrid AID with either faster-acting insulin aspart or standard insulin aspart in random order. During both interventions, participants were using the hybrid AID (investigational version of MiniMedTM 780G, Medtronic). Participants were encouraged to exercise as frequently as possible, capturing physical activity with an activity monitor. The primary outcome was the percentage of sensor glucose time above range (180 mg/dL measured by continuous glucose monitoring.

      In an intention-to-treat analysis, mean time above range was 31%±15% at baseline, 19%±6% during faster-acting and 20%±6% during standard insulin aspart use with no difference between treatments. Similarly, there was no difference in mean time in range (78% and 77%) or median time below range (2.5% and 2.8%) for the two insulins. Glycemic outcomes during exercise or postprandial periods were comparable for the two treatment arms. The study did not report any severe hypoglycemia or diabetic ketoacidosis events. In children and adolescents with type 1 diabetes who engage in physical activity, faster-acting insulin aspart was not superior to regular aspart when used with a hybrid AID system. However, even during and after reported exercise, both insulin formulations provided high overall time in range and low time above and below range.

Read More